High materiality9/10
Damora Therapeutics price target raised, named a Best Idea at Guggenheim
Why it may matterVerify against the original reporting
Strong upside potential from upgrade; favorable risk-reward.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Guggenheim raises DMRA target to $60; current price $20.13; DMRA named a Best Idea by the firm.
- Guggenheim raises DMRA target to $60; price $20.13.; Best Idea.
Key facts
- 01
Target: $60
- 02
Posted price: $20.13
- 03
Analyst firm: Guggenheim
- 04
Analyst: Brad Canino
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.